Compare Cytokinetics Inc (CYTK) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Toronto-Dominion Bank — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Toronto-Dominion Bank trades at $114.14 (market cap $186.61B). The key difference: Toronto-Dominion Bank is far larger — about 22× Cytokinetics Inc's market cap, and Toronto-Dominion Bank pays a 2.84% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Toronto-Dominion Bank for 84 Days on average.
| CYTK | TD | |
|---|---|---|
Market Cap | $8.50B | $186.61B |
Volume | 2,395,556 | 4,056,663 |
Sector | Health | Financials |
52-Week High | $87.26 | $124.80 |
52-Week Low | $54.76 | $78.32 |
Typical Hold Time | 19 Days | 84 Days |
Enterprise Value | $8.60B | $559.39B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
TD stock trades at $114.04, down 3.5% today, with a bearish technical signal. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $1.98 versus $1.74 expected. The company announced a $10 billion share buyback program and is expanding its U.S. branch network. Revenue grew to $61.28 billion in 2025, with a net income margin of 24.88%.
The outlook is mixed: strong profitability and analyst buy ratings support upside, but bearish technicals and volatile cash flows pose risks. The stock's valuation appears reasonable with a P/E of 17.39. Key risks include execution of expansion plans and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
